Free tool
FAERS Monitor: Xyzal Allergy 24hr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209089 or its brand name (Xyzal Allergy 24hr, Levocetirizine Dihydrochloride). Reports on generic versions are filed under their own applications.
Reports
9,447
Serious
2,266
24% of reports
Hospitalization
1,001
Death reported
287
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,857
- somnolence1,373
- fatigue764
- headache472
- pruritus425
- diarrhoea382
- nausea377
- dyspnoea376
- dizziness358
- insomnia313
- cough303
- therapeutic response decreased280
- feeling abnormal272
- arthralgia270
- no adverse event241
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 5 |
| 2006 | 5 |
| 2007 | 3 |
| 2008 | 15 |
| 2009 | 25 |
| 2010 | 18 |
| 2011 | 78 |
| 2012 | 61 |
| 2013 | 26 |
| 2014 | 33 |
| 2015 | 54 |
| 2016 | 85 |
| 2017 | 907 |
| 2018 | 1,509 |
| 2019 | 559 |
| 2020 | 404 |
| 2021 | 1,649 |
| 2022 | 914 |
| 2023 | 837 |
| 2024 | 836 |
| 2025 | 855 |
| 2026 | 569 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,712 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| somnolenceSignal | 1,373 | 15.3 | 14.5 | 18,358 |
| therapeutic response decreasedSignal | 280 | 10.3 | 9.2 | 2,345 |
| drug ineffectiveSignal | 1,857 | 3.1 | 3.0 | 2,883 |
| no adverse eventSignal | 241 | 3.0 | 2.6 | 314 |
| insomniaSignal | 313 | 2.6 | 2.3 | 315 |
| feeling abnormalSignal | 272 | 2.5 | 2.2 | 252 |
| pruritusSignal | 425 | 2.5 | 2.2 | 375 |
| coughSignal | 303 | 2.4 | 2.2 | 251 |
| fatigueSignal | 764 | 2.2 | 2.0 | 509 |
| headache | 472 | 1.7 | 1.5 | 132 |
| dizziness | 358 | 1.6 | 1.4 | 81 |
| dyspnoea | 376 | 1.5 | 1.3 | 59 |
| arthralgia | 270 | 1.4 | 1.3 | 37 |
| diarrhoea | 382 | 1.3 | 1.2 | 30 |
| nausea | 377 | 1.1 | 1.0 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.